CATO SMS\u00a0announced that it has acquired Wilmington, NC-based\u00a0Array Biostatistics\u00a0(Array) to expand its offering of specialized clinical research solutions.\u00a0 The company plans to invest in growing Array and its highly regarded biostatistical capabilities.<\/p>\n\n\n\n
Both Array and CATO SMS offer highly specialized services that expedite and support drug development for small and emerging biopharmaceutical companies. By acquiring Array, CATO SMS adds expertise and scale to its full-service biostatistical consulting, analysis and programming capabilities. CATO SMS will focus on growing these capabilities and its team of senior biostaticians and statistical programmers, as it continues to expand its product development consulting and clinical trial operations. Sandy Ferber, chief executive officer of Array, will continue to lead Array and will spearhead CATO SMS\u2019 overall biometrics offering.<\/p>\n\n\n\n
\u201cWe are thrilled to have this opportunity to grow our biostatistical offering in partnership with CATO SMS. Together, we share core values centered around high quality and a commitment to providing our clients with expert and highly personalized service. We have already identified a number of areas where, as a result of our combination, we will be able to provide our clients with enhanced capabilities in the future,\u201d said Ms. Ferber.<\/p>\n\n\n\n
Mark A. Goldberg, M.D., executive chairman, CATO SMS, added, \u201cWe are excited to welcome Array\u2019s impressive team to CATO SMS. They are differentiated by their consultative approach, wealth of industry experience and commitment to client satisfaction. The Array acquisition furthers our goal of providing our clients with a comprehensive portfolio of specialized solutions to best support development in complex therapeutic areas including oncology, rare and orphan indications, and cell and gene therapy, among others.\u201d<\/p>\n\n\n\n
CATO SMS\u2019 acquisition of Array marks another advancement in the company\u2019s strategic expansion.\u00a0 The company was formed in 2019 when Cato Research merged with SMS-oncology.\u00a0 Working together with healthcare investors, Water Street Healthcare Partners and JLL Partners, CATO SMS has extended its global footprint, deepened its oncology and regulatory expertise, and bolstered its suite of solutions. With offices across North America, Europe, and the Middle East, CATO SMS conducts trials in more than 20 countries.\u00a0 To date, the company has contributed to the successful development of more than 50 marketed products.<\/p>\n\n\n\n